Emplicure AB Year-end Report 2021 - Further pieces in place to deliver upon our promises in 2022
Fourth quarter, 1 October - 31 December 2021
· Net revenue totalled 0.0 (0.1) MSEK
· EBIT totalled -5.2 (-1.6) MSEK
· EBITDA totalled -5.1 (-1.6) MSEK
· Cash flow totalled -4.6 (+0.6) MSEK
· Earnings per share -0.25 (-0.14) SEK
Accumulated, 1 January - 31 December 2021
· Net revenue totalled 0.1 (0.6) MSEK
· EBIT totalled -16.7 (-4.6) MSEK
· EBITDA totalled -18.4 (-4.6) MSEK
· Cash flow totalled +18.8 (+2.5) MSEK
· Earnings per share -1.16 (-0.43) SEK
· Emplicure was listed on Nasdaq First North Growth Market
Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via email@example.com
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on February 22, 2022 at 08:30 CET.
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com
Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.
Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.
Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.
Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.